• Biohaven’s third-quarter 2026 net loss narrowed 25% year over year to $129.28 million.
• Research and development expenses fell 28% to $101.85 million, primarily due to lower direct program and preclinical spending.
• The SK Biopharmaceuticals licensing agreement provides $400 million in cash consideration, including $350 million payable at closing.
• The FDA paused new opakalim enrollment pending additional nonclinical safety studies; RISE 3 topline results remain expected in second-half 2026.
• The FDA accepted the Vyglxia application resubmission for spinocerebellar ataxia, assigning a first-quarter 2027 user fee goal date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610291602PR_NEWS_USPR_____NE84836) on October 29, 2026, and is solely responsible for the information contained therein.